CLAIMS

1. A composition comprising an E6 or E7 protein or E6/E7 fusion protein from HPV optionally linked to an immunological fusion partner, and an immunomodulatory CpG oligonucleotide.

2. A composition as claimed in claim 1 wherein the fusion partner is selected from the group; protein D or a fragment thereof from Heamophilius influenzae B, lipoprotein D or fragment thereof from Heamophilius influenzae B, NS1 or fragment thereof from Influenzae Virus, and LYTA or fragment thereof from Streptococcus Pneumoniae.

3. A composition as claimed in claim 1 or 2 wherein the E6 or E7 proteins are derived from HPV16 or HPV18.

4. A composition as claimed in claim 1, 2 or 3 wherein the E7 protein is mutated.

5. A composition as claimed in claim 1, 2 or 3 wherein the E6 protein is mutated.

6. A composition as claimed in any of claims 1 to 5 additionally comprising a histidine tag of at least 4 histidine residues.

7. A composition as claimed herein comprising an additional HPV antigen.

8. A composition as claimed herein where the immumodulatory CpG oligonucleotide comprises a hexamer motif: purine purine cytosine guaine pyrimidine pyrimidine.

9. A composition as claimed herein wherein the immunomodulatory CpG oligonucleotide has two or more CpG motifs.

10. A composition as claimed herein wherein the CpG oligonucleotide contains a phosphorothioate inter-nucleotide linkage.

11. A composition as claimed herein wherein the CpG oligonucleotide is selected from the group:

OLIGO 1: TCC ATG ACG TTC CTG ACG TT

OLIGO 2: TCT CCC AGC GTG CGC CAT

OLIGO 3: ACC GAT GAC GTC GCC GGT GAC GGC ACC ACG

~~12. A composition as claimed herein for use in medicine.~~

sub A3

13. A method of inducing an immune response in a patient to an HPV antigen comprising administering a safe and effective amount of a composition as claimed herein.

14. A method of preventing or treating HPV induced tumours in a patient comprising administering a safe and effective amount of a composition as claimed herein.

15. A method of preparing a composition as claimed herein, comprising admixing an E6, E7 or E6/E7 fusion protein optionally linked to an immunological fusion partner, and an immunomodulatory CpG oligonucleotide.

add A4

add B5

add C5